$NVLX Readies for Late-Stage Trials as NCI Seeks New

New Post Public Reply Private Reply Replies (1) Message Board
PYCKtradr PYCKtradr #28027

$NVLX Readies for Late-Stage Trials as NCI Seeks New Pancreatic Cancer Drugs

National Cancer Institute Seeking a New Pancreatic Cancer Treatment as Death Rates Rise

December 20, 2013 /

There may be a more optimistic future on the horizon for those afflicted by pancreatic cancer. Currently, Eli Lilly’s (LLY) Gemzar® (gemcitabine) is the only single?agent FDA ? approved (in 1996) drug to treat the disease that a November article in the Journal of the National Cancer Institute stated will become the number two cause of cancer deaths in the next decade. In September, the FDA approved Celgene’s (CELG) Abraxane®, a nanoparticle formulation of albumin with the widely used anticancer drug paclitaxel (Taxol®), in combination with gemcitabine. Major reasons for the FDA approval of the Abraxane® plus gemcitabine combination included a median survival time of 8.5 months as compared to 6.7 months for gemcitabine alone and a one?year survival rate that was increased by 59% over that seen with gemcitabine alone. Shares of Celgene have more than doubled in 2013 to $170, in part because of the approval of the Abraxane/gemcitabine combination.


What if there’s something even better than Gemzar® (gemcitabine) or Abraxane + gemcitabine?

Nuvilex, Inc. (NVLX) may be bringing that caliber of a therapeutic down its pipeline with its treatment for pancreatic cancer that is composed of the well?known anti?cancer prodrug ifosfamide and the cellulose?based, live?cell encapsulation technology for a variety of hard?to?treat diseases, such as cancer and diabetes. As a prodrug, ifosfamide must be converted (activated) into its cancer killing form before it is effective. The cell encapsulation technology, called “Cell?in?a?Box™,” is a novel platform that puts ifosfamide?activating cells into pin?head?sized, spherical capsules that are then implanted into patients with advanced, inoperable pancreatic cancer, near the pancreas and therefore the tumor itself. By activating the anti?cancer drug very near the tumor, the cancer?killing effects of the ifosfamide are optimized.

In Phase 1/2 clinical trials using the Cell?in?a?Box™/ifosfamide combination treatment, when the results were compared with those from pivotal studies used by the FDA to approve Gemzar®, the Cell? in?a?Box™/ifosfamide combination gave a median survival time of 11 months as compared to 5.7 months for Gemzar® and a one?year survival rate (36%) that was double that seen with Gemzar®. By comparison, as noted above, in the pivotal trial that led to the approval of Celgene’s Abraxane®/gemcitabine combination, patients treated with that combination had a one?year survival rate that was 59% greater than that for gemcitabine and a median survival time of 8.5 months versus 6.7 months with gemcitabine alone.


If the above apparent superiority of the Cell?in?a?Box™/ifosfamide combination as compared to either Gemzar® or the Abraxane®/gemcitabine combination sounds amazing, that’s because it is, particularly if one realizes that, since 1996, only two treatments have been approved by the FDA for the treatment of advanced, inoperable pancreatic cancer with the latest and best being Celgene’s Abraxane®/gemcitabine combination.


But it even gets better. Whereas serious side effects were seen in patients receiving treatment with Gemzar® or the Abraxane®/gemcitabine combination, no serious side effects were seen in patients treated with the Cell?in?a?Box™/ifosfamide combination. This is because, patients in the Phase 1/2 trials with the latter combination were given ifosfamide at only one?third of the dose normally administered when this anti?cancer drug is used alone to treat cancers, whereas patients in the pivotal trials for Gemzar® or the Abraxane®/gemcitabine combination were given the highest doses that they could tolerate. The reduced side effect profile seen with the Cell?in?a?Box™/ifosfamide treatment resulted in an overall better “quality?of?life” for the patients.

Nuvilex is in the midst of preparing for late?stage trials to evaluate the Cell?in?a?Box™/ifosfamide combination directly against gemcitabine, similar to what Celgene just did. If the results replicate the Phase 1/2 data and outperform not only gemcitabine, but also the Abraxane®/gemcitabine combination, whil e at the same time reducing the side effects associated with the treatment of advanced, inoperable pancreatic cancer, the days of Nuvilex trading at 12 cents per share will be a distant memory. Savvy biotech investors know that the time to invest is before clinical data arrives in order to catch the full breadth of a move, particularly if positive top?line results are delivered, meaning that now, not later, is the time to be taking a close look at Nuvilex, Inc. (NVLX) and its acquisition of the rights to use a unique live?cell encapsulation technology that could revolutionize treatments for pancreatic cancer as well as other deadly diseases.


About Baystreet Media Group (BMG): BMG is a full service Investment Relations firm. For more information and to read disclaimers and disclosures: www.baystreetmediagroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 519

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 113

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 328

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading